Search results for "Progression"

showing 10 items of 1251 documents

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response…

2008

Abstract Introduction: Previous phase II studies have suggested that a combination of FCR may increase the outcome of both untreated and relapsed CLL pts. In order to validate this concept the German CLL study group (GCLLSG) initiated a multicentre, multinational phase III trial, CLL8, to evaluate the efficacy and tolerability of FCR versus FC for the first-line treatment of pts with advanced CLL. Methods and Patients: 817 pts with good physical fitness as defined by a cumulative illness rating scale (CIRS) score (Extermann et al., JCO 1998) of up to 6 and a creatinine clearance (cr cl) □d 70 ml/min were enrolled between July 2003 and March 2006. Pts were randomly assigned to receive 6 cour…

medicine.medical_specialtyCyclophosphamideImmunologychemical and pharmacologic phenomenaNeutropeniaBiochemistryGastroenterology03 medical and health sciences0302 clinical medicineChemoimmunotherapyInternal medicinemedicineProgression-free survivalLeukopeniabusiness.industryCell BiologyHematologymedicine.disease3. Good healthSurgeryFludarabineTolerability030220 oncology & carcinogenesisConcomitantmedicine.symptombusiness030215 immunologymedicine.drugBlood
researchProduct

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

2014

Pseudomonas aeruginosa is the main pathogen in bronchopulmonary infections in cystic fibrosis (CF) patients. It can only be eradicated at early infection stages while reduction of its bacterial load is the therapeutic goal during chronic infection or exacerbations. Neonatal screening and pharmacokinetic/pharmacodynamic knowledge has modified the management of CF-patients. A culture based microbiological follow-up should be performed in patients with no infection with P. aeruginosa. At initial infection, inhaled colistin (0,5-2 MU/tid), tobramycin (300 mg/bid) or aztreonam (75 mg/tid) with or without oral ciprofloxacin (15-20 mg/kg/bid, 2-3 weeks) are recommended. In chronic infections, trea…

medicine.medical_specialtyCystic Fibrosismedicine.drug_classAntibioticsAztreonammedicine.disease_causeCystic fibrosisCystic fibrosischemistry.chemical_compoundInternal medicinemedicineTobramycinHumansPseudomonas InfectionsIntensive care medicinebusiness.industryPseudomonas aeruginosaGeneral Medicinemedicine.diseaseAntibiotic treatmentAnti-Bacterial AgentsCiprofloxacinChronic infectionchemistryChronic DiseasePseudomonas aeruginosaDisease ProgressionColistinbusinessBronchial infectionmedicine.drugArchivos de Bronconeumología (English Edition)
researchProduct

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT …

2010

Abstract Abstract 877 This phase-III randomized EBMT-intergroup trial studied the impact of a consolidating autoHSCT vs no consolidation for patients with CLL in Binet stage A progressive, B or C , in CR, nodular PR or VGPR after first or second line therapy. The primary objective was to show that autoHSCT increased the 5-year progression-free survival (PFS) by 30%. Although it had been calculated that 270 patients were to be randomized, the study was terminated by the steering committee in July 2007 due to poor accrual. Here we present a first analysis based on 69% of expected follow-up forms. Results: Between November 2001 and July 2007, 223 patients were enrolled (SFGM-TC/FCLLG n=98, MRC…

medicine.medical_specialtyDisease statusRandomizationbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)ImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrySurgerylaw.inventionRandomized controlled triallawInternal medicinemedicineIn patientProgression-free survivalStage (cooking)business
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Voluntary distance running prevents disease progression in mice with non-alcoholic fatty liver disease (NAFLD)

2019

medicine.medical_specialtyDistance runningbusiness.industryInternal medicineFatty liverDisease progressionmedicineNon alcoholicDiseasemedicine.diseasebusinessGastroenterology35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
researchProduct

Nursing care in therapeutic hypothermia in neonates with hypoxic-ischaemic encephalopathy. Review of the literature

2018

Abstract Introduction Hypoxic-ischaemic encephalopathy is one of the main causes of neurological damage in the new-born. Therapeutic hypothermia is the current treatment to reduce mortality and disability in new-borns with this condition. Objective To identify nursing care in new-borns with severe to moderate EHI, treated with active therapeutic hypothermia. Materials and methods A review of the scientific literature was carried out in different databases (PubMed, Lilacs, IBECS, Cinhal, OvidSP, Cuiden, Embase and Cochrane Plus) over the last five years. The documentary assessment was carried out by peers and the quality was evaluated using the CEBM and GRADE scales. Results Of the 22 articl…

medicine.medical_specialtyEmotional supportHypothermia treatmentMedical treatmentbusiness.industryEncephalopathyInfant NewbornEarly detectionHypothermiamedicine.diseaseHypoxic ischaemic encephalopathyNursing careHypothermia InducedHypoxia-Ischemia BrainDisease ProgressionmedicineHumansmedicine.symptombusinessIntensive care medicineEnfermería Intensiva (English ed.)
researchProduct

Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant.

2006

Abstract To test the significance of human papillomavirus (HPV) type 16 and HPV16 E6 variants as risk factors for viral persistence and progression to high-grade lesion, we did a nested case-control study within a cohort study of >15,000 Caucasian French women. Three groups infected with high-risk HPV were compared: (a) women with cleared infection (controls, n = 201), (b) women with persistent infection (cases, n = 87), and (c) women who progressed into high-grade lesion (cases, n = 58). Women with persistent HPV infection and those that progressed into high-grade lesions were likelier to harbor HPV16 than other high-risk HPV types [odds ratio (OR), 2.4; 95% confidence interval (95%…

medicine.medical_specialtyEpidemiologyUterine Cervical NeoplasmsCervical intraepithelial neoplasiaLesionCohort StudiesRisk FactorsInternal medicineEpidemiologymedicineOdds RatioHumansRisk factorbusiness.industryPapillomavirus InfectionsHPV infectionvirus diseasesOdds ratioOncogene Proteins Viralmedicine.diseaseUterine Cervical DysplasiaRepressor ProteinsOncologyCase-Control StudiesImmunologyDisease ProgressionFemaleViral diseaseFrancemedicine.symptombusinessCohort studyCancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
researchProduct

Superficial esophageal cancer: endoscopic resection or radical surgery?

2010

medicine.medical_specialtyEsophageal Neoplasmsbusiness.industryGeneral surgeryEndoscopyEndoscopic submucosal dissectionEsophageal cancermedicine.diseaseSurgeryOncologymedicineBiomarkers TumorCarcinoma Squamous CellDisease ProgressionHumansLymph Node ExcisionPharmacology (medical)Endoscopic resectionRadical surgerybusinessNeoplasm StagingExpert review of anticancer therapy
researchProduct

Type 2 diabetes mellitus and osteoarthritis

2019

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the saf…

medicine.medical_specialtyEvidence-based practicetype 2 diabetes mellituendocrine system diseasesMedicinaOsteoarthritisOverweightPathophysiologyArticle03 medical and health sciences0302 clinical medicineInsulin resistanceRheumatologyInternal medicineOsteoarthritisType 2 diabetes mellitusMedicineHumans030212 general & internal medicineObesityRisk factor030203 arthritis & rheumatologyddc:616[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systembusiness.industryType 2 Diabetes Mellitusnutritional and metabolic diseases[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseObesity3. Good healthInstitutional repositoryAnesthesiology and Pain MedicineDiabetes Mellitus Type 2[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemDisease Progressionosteoarthritimedicine.symptomInsulin ResistanceSafetybusiness
researchProduct

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis

2022

Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensit…

medicine.medical_specialtyExacerbationbiologicals monoclonal antibodies observational studies precision medicine real-lifeprecision medicineImmunologyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin EAntibodies Monoclonal Humanizedobservational studiechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyCluster AnalysisHumansAnti-Asthmatic Agentsreal-lifeobservational studiesmonoclonal antibodieResponse rate (survey)Bronchiectasisbiologybusiness.industrymedicine.diseaseBenralizumabPhenotypeAsthmaEosinophilsPhenotypechemistrybiologicalsbiology.proteinDisease ProgressionBiomarker (medicine)monoclonal antibodiesbusinessbiological
researchProduct